Article
ECT for Treatment-Resistant Depression: When to Consider It and What to Expect
Treatment options
Treatment options
- Treatment-resistant depression (TRD) affects around 30% of people with depression: defined as no adequate response to at least two antidepressant trials at therapeutic doses
- TRD is managed through a stepped approach: medication optimisation, psychotherapy, then brain stimulation if symptoms persist
- ECT is the most intensive brain stimulation option: hospital-based, performed under general anaesthesia, inducing a brief controlled seizure
- ECT is highly effective: response rates of 60 to 80% and improvement often within 1 to 2 weeks, making it valuable in high-risk or severe cases
- The main concern with ECT is memory: short-term confusion and retrograde amnesia are common, though most cognitive function improves over time
- Less invasive options should be tried first: tDCS (Flow) is the least invasive and home-based; TMS is clinic-based and FDA-approved for TRD; ECT is reserved for severe or urgent cases
- Flow's tDCS is worth trying earlier in the pathway: low risk, evidence-supported, and may reduce the need to escalate to more intensive treatments
- ECT is not always a last resort: it may be offered earlier in cases of acute suicidal risk, psychotic depression, or catatonia
For approximately 30% of people who have major depressive disorder, standard treatment methods do not work. This medical condition exists as treatment-resistant depression (TRD).
When symptoms continue despite different attempts, electroconvulsive therapy (ECT) may help. ECT for treatment-resistant depression can provide effective results, although people frequently misunderstand it.
In this guide, we will talk about TRD, when ECT for treatment-resistant depression is recommended, and how it compares to other brain stimulation like transcranial magnetic (TMS) and transcranial direct current (tDCS), including Flow.
What Is Treatment-Resistant Depression?
Here we’ll clarify TRD and how common this experience actually is.
A clinical treatment-resistant depression definition describes depression that hasn’t adequately responded to at least two separate antidepressant trials at therapeutic doses for a minimum of 6–8 weeks each. An adequate response usually means a 50% reduction in symptoms on standardized rating scales. That’s why TRD is sometimes referred to as medication resistance.
TRD reflects the complexity of depression and how it responds to treatment, not a different type or severity of depression or a lack of effort. It does not mean recovery is impossible; it just indicates that standard first-line treatments not yet provided sufficient relief. Many people with TRD improve with adjusted, combined, or alternative treatments.
How Common Is It?
Research shows that 30% of people with depression experience TRD. Because it’s so common, established healing pathways exist.
The Stepped Approach to Treating TRD: Where ECT Fits
TRD is usually managed through a structured, stepwise approach.
Step 1 - Medication Optimization
The first step is to ensure antidepressants have been used at therapeutic doses for a sufficient time. If there is no response, doctors switch antidepressants or use augmentation strategies with lithium, thyroid hormones, or certain antipsychotics. Often, 4–6 strategies are tried before moving forward. This careful approach ensures that ECT after failed antidepressants is only considered when necessary.
Step 2 - Adding or Switching to Psychotherapy
The second step requires adding or doing more intensive psychotherapy, like CBT, IPT, or psychodynamic. It often works best when paired with medications. In complex cases, a therapist experienced with TRD may be essential.
Step 3 - Brain Stimulation Options
If symptoms persist, the third step is neuromodulation. These form a continuum of care, from less to more intensive procedures:
Transcranial Direct Current Stimulation (tDCS) – Flow
It is the least invasive procedure, as it delivers a gentle electrical current to the brain. tDCS is home-based and usually used with therapy or medication.
tDCS technology used in Flow is suited for adults who have a diagnosis of mild to moderate and even severe depression. It is perfect as an add-on in TRD and recommended to try earlier in the pathway.
Flow has FDA approval for at-home depression treatment
Transcranial Magnetic Stimulation (TMS):
TMS goes in the middle, as it’s not invasive, but still clinic-based. The effect comes from magnetic pulses that stimulate mood-related brain regions.
Treatment does not require anaesthesia, daily sessions are organised over 4-6 weeks, and it is more intensive than tDCS, but less than ECT.
It’s worth noting that TMS is FDA-approved for TRD.
Electroconvulsive Therapy (ECT):
ECT is the most effective and intensive, as well as hospital-based, treatment. It induces a brief controlled seizure and is performed under general anesthesia in a hospital. ECT for treatment-resistant depression is reserved for severe cases and comes with the largest side-effect profile.
When Is ECT Typically Recommended for Treatment-Resistant Depression?
Some of you may ask: “When is ECT recommended?” Truth is, ECT for treatment-resistant depression isn’t always a “last resort” and may be offered earlier in certain cases. Below are common scenarios when ECT is proposed:
Severe Depression with Immediate Risk
And particularly, if there is an active suicidal risk, psychotic depression, catatonia, severe malnutrition due to inability to eat, or other cases when there is a need for rapid improvement.
Multiple Treatment Failures
It’s especially considered after several medication trials, psychotherapy, and other brain stimulation methods such as TMS or tDCS fail to produce sufficient improvement.
Previous Positive Response to ECT
If ECT worked for you in the past, it may be offered again. It is documented in research that patients who responded well previously often respond well again.
Patient Preference
Some patients actually choose ECT after being fully informed, mostly because of its fast effect or difficulties tolerating medications.
What an ECT Course Involves: Procedure and Timeline
These practical details will help you better understand the ECT procedure.
The Procedure Itself
It is performed in a hospital under general anesthesia (lasting 5–10 minutes) and a short-acting muscle relaxant. Electrodes deliver a controlled electric stimulus to the brain, triggering a 30–60 second seizure. The patient wakes up after 5–15 minutes, is monitored until confusion clears, usually within an hour, and can often go home the same day.
Treatment Course Timeline
The first course setup includes 6–12 sessions over 2–4 weeks, happening 2–3 times per week. The course may be extended if the patient’s condition hasn’t improved enough.
After the Initial Course
Maintenance ECT (once weekly or monthly) or medication may follow to support relapse prevention. It requires repeated hospital visits and a time commitment.
ECT Effectiveness: What the Evidence Shows
ECT for treatment-resistant depression remains widely used because of scientifically proven ECT effectiveness.
Response Rates
ECT produces response rates of 60–80% in TRD, translating into at least 50% symptom reduction. Remission occurs in 30–50% cases.
Speed of Response
Improvement often occurs within 1–2 weeks, making ECT for treatment-resistant depression valuable in high-risk situations.
Particular Effectiveness
Very effective for psychotic depression, catatonia, and in older patients who are intolerant of medications.
The Relapse Challenge
Without continued treatment, 37–51% cases experience relapse within six months. Maintenance strategies are essential. However, the effectiveness is real, and that's why ECT is still used despite side effects.
Weighing ECT Side Effects Against Benefits
ECT also carries risks that should be clearly understood. For more details, check the “ECT Side Effects” article.
Common Short-Term Effects
Common short-term but manageable effects include confusion immediately after treatment (which clears within hours), headaches (though manageable with painkillers), muscle aches, and nausea (often from anaesthesia).
Memory Effects – The Main Concern
Memory effects are the main concern. The ones that occur often are short-term memory problems and retrograde amnesia, with gaps in memories from weeks or months before treatment. For most, cognitive function improves within months, yet some report lasting memory gaps.
The Decision Context
Before ECT for treatment-resistant depression, weigh the memory risks against the impact of depression. For some, severe depression is more disabling than potential memory effects, and that’s why this is a very individual decision that should be made together with the medical team.
How ECT Compares to TMS and tDCS for Treatment-Resistant Depression
Here we compare brain stimulation methods for TRD, including ECT vs tDCS.
tDCS - Flow
It is the least invasive technology. Flow’s treatment is a home-based mild electrical stimulation consisting of 30-minute sessions. The Flow is supported by science for mild-to-moderate depression and can help in TRD as an add-on.
Improvements often become visible in 3–4 weeks. Side effects are minimal (mild tingling or headache).
tDCS can reduce the need for more intensive interventions, though it is not a replacement for ECT for TRD in severe cases. We want to emphasize that tDCS is worth trying earlier in the treatment pathway.
TMS
TMS is slightly more invasive. It is based on clinic-based delivery of magnetic pulses, with no anesthesia or surgeries needed. As mentioned earlier, it is FDA-approved for TRD.
Daily sessions are administered over 4–6 weeks. Side effects are mild, and memory is unaffected. In discussions of ECT vs TMS treatment-resistant depression, TMS shows response rates of 40–60%, lower than ECT.
ECT
It is the most intensive treatment. ECT consists of hospital-based triggered seizure under anesthesia, with the fastest onset (1–2 weeks), initial course of 2–4 weeks, and the highest response rates (60–80%).
Side effects include memory concerns, confusion, and headaches. Reserved for severe TRD. It is often considered when other options fail, or when a rapid response is critical.
Questions to Ask When Considering ECT
These are the things to ask the psychiatric team to make an informed choice:
About Treatment Options
First, ask whether all other options (medication adjustments, intensive psychotherapy, TMS, tDCS) have been fully explored. Ask why ECT for treatment-resistant depression is being recommended now. Finally, analyse what makes you think I'll respond to ECT.
About the Procedure
Think about the procedure, too. It is important to understand what type of ECT (bilateral vs. unilateral; brief vs. ultra-brief pulses) will be used, what the number of sessions is, and what happens during and after treatment sessions.
About Outcomes and Risks
Raise questions like when to expect improvement, and how the risks will be handled. It is also crucial to understand what happens if you experience severe memory problems.
About Aftercare
Further on, as whether relapse prevention, maintenance, and support strategies will be provided. Make sure you are provided with information on how to prevent relapse and what support is available during treatment.
About Experience
Make sure you understand the doctor’s experience with managing side effects in patients like you. Also, ask if you can speak with someone who's been through ECT treatment in that specific location.
Before ECT: Other Options Worth Trying
Before escalating to ECT for treatment-resistant depression, less invasive options should be carefully considered.
Thorough Medication Review
Ensure adequate medication options, different augmentation strategies, and combination therapies have been explored. A second opinion from a psychopharmacologist may help.
TMS If Accessible
TMS is less invasive than ECT, as noted earlier. Also, it is FDA-approved for TRD, so it is definitely worth trying if available in your area.
tDCS as an At-Home Option
tDCS is a low-risk, evidence-supported TRD add-on that can be used with therapy and medication. The flow device is also validated in a large trial, and 77% of 55,000+ users across the world have reported improvement. Flow tDCS use may prevent escalation to ECT.
Intensive Therapy Programs
Day or intensive outpatient programs specializing in TRD, as well as specialist TRD therapy approaches, can provide better support than standard therapy.
Physical Health Factors
Try to address sleep first, as it can be perpetuating depression. Check your thyroid health, monitor vitamin D levels, nutrition, and exercise.
Understanding these techniques can help you make more informed decisions. We created Flow to help people avoid needing ECT by addressing depression earlier with less invasive options. It is one of the few techniques worth trying before escalating to ECT, as part of a comprehensive approach.
Conclusion
At this point, it is commonly accepted that the treatment of TRD requires a stepped care approach. ECT for treatment-resistant depression achieves high effectiveness because it produces 60-80% response rates while patients experience improvement within 1-2 weeks.
The main bad side is that patients face the danger of anesthesia and memory loss.
Before ECT, it’s important to explore medications, intensive psychotherapy, and less invasive brain stimulation methods like tDCS (Flow) or TMS. When a patient needs immediate relief from their condition or all other methods have failed, ECT becomes the “gold standard” treatment. The decision to choose ECT should be made with the psychiatric team, weighing all benefits and risks.